Asthma and risk of myelodysplastic syndromes: a population-based cohort study | Aplastic Anemia and MDS International Foundation

Asthma and risk of myelodysplastic syndromes: a population-based cohort study

Journal Title: 
Br J Cancer
Primary Author: 
Frederiksen H
Author(s): 
Frederiksen H, Farkas DK, Horváth-Puhó E, Nørgaard JM, Nørgaard M, Sørensen HT
Original Publication Date: 
Tuesday, November 29, 2016

BACKGROUND:

Risk factors for the development of myelodysplastic syndromes (MDS) include age, exposure to ionising radiation, and cytotoxic drug treatment. Recently, asthma also has been suggested as a risk factor for MDS.

METHODS:

We undertook this nationwide population-based cohort study on patients with a first-time hospital-based asthma diagnosis during 2002-2013 and followed them for the development of MDS/chronic myelomonocytic leukaemia (CMML).

RESULTS:

We identified 75 995 patients with incident asthma and no previous MDS/CMML diagnosis. Seventy-eight patients subsequently developed MDS and nine patients developed CMML during 402 892 person-years. The cumulative risks of developing MDS/CMML among asthma patients were 0.02% (95% CI: 0.01-0.04%) and 0.07% (95% CI: 0.05-0.09%) during the first year and the first five years of follow-up, respectively. The standardised incidence ratio of MDS/CMML among asthma patients overall was 1.6 (95% CI: 1.3-2.0) with little variation across subgroups.

CONCLUSIONS:

Asthma may be a risk factor for the development of MDS/CMML.

Bone Marrow Diseases: